ArQule, Inc. to Present at Leerink Swann Cancer Roundtable on May 20, 2009.

WOBURN, Mass. -- In release dated May 13, 2009, the presentation time has been changed to 9:45 a.m. eastern time (sted 9:15 a.m. eastern time).

The corrected release reads:

ARQULE, INC. TO PRESENT AT LEERINK SWANN CANCER ROUNDTABLE ON MAY 20, 2009

ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Leerink Swann Cancer Roundtable Conference on Wednesday, May 20, 2009 at 9:45 a.m. eastern time. ArQule's presentation will be web cast live and can be accessed through the investor relations section of the Company's website, www.arqule.com. The conference will be held at the Roosevelt Hotel in New York.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. An additional clinical-stage program includes compounds that activate the cell's DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company's pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP[TM]) are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate).